Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin

Fractyl Health announced that the company has received approval from the FDA for an Investigational Device Exemption (IDE) to begin its Revitalize-2 pivotal study.